Physician profile

Stefan Gluck

Hematology & Oncology · Miami, FL

NPI 1417913781

$49,126.19

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$3,650.00
Food and Beverage$142.27

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Puma Biotechnology, INC. $45,015.21 2019-2020
Novartis Pharmaceuticals Corporation $2,000.00 2024
Secura Bio, INC. $1,650.00 2023 Copiktra
Coherus Oncology, INC. $142.27 2024
Astrazeneca Pharmaceuticals Lp $132.50 2021
Nanostring Technologies, INC. $117.27 2019
Veracyte, INC. $43.38 2020
Qt Imaging, INC. $25.56 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Stefan Gluck

$49,126.19

in general payments reported 2019-2025

Years
2019-2024
Top company
Puma Biotechnology, INC.

https://glasscript.com/doctor/63758/stefan-gluck

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.